Last reviewed · How we verify
hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Alhemo | CONCIZUMAB | Novo Nordisk Inc | Tissue Factor Pathway Inhibitor Antagonist [EPC] | 2024-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Novo Nordisk Inc · 1 drug in hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors:
- hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors treatment updates — RSS
- hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors treatment updates — Atom
- hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors treatment updates — JSON
Cite this brief
Drug Landscape (2026). hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hemophilia-b-congenital-factor-ix-deficiency-with-or-without-fix-inhibitors. Accessed 2026-06-10.
Related
- hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing